Table 1 Selected agents in first line for advanced HCC
From: Emerging therapies in advanced hepatocellular carcinoma
Trial | Phase | Mechanism of action | Primary endpoint | OS (months) | PFS (months) | ORR (%) |
|---|---|---|---|---|---|---|
Sorafenib vs placebo (SHARP) | III | Multi-targeted TKI | OS | 10.7 vs 7.9 months (p < 0.001) | 5.5 vs 2.8 months (p < 0.001) | 2 |
Lenvatinib vs sorafenib (REFLECT) | III | Multi-targeted TKI | OS, non-inferiority | 13.6 vs 12.3 months (HR = 0.92; 95% CI 0.79–1.06) | 8.9 vs 3.7 months (p < 0.0001) | 24.1 vs 9.2 (p < 0.0001) |
Sunitinib vs sorafenib | III | Multi-targeted TKI | OS | 7.9 vs 10.2 months (p = 0.0014) | 3.6 vs 3.0 months (p = 0.22) | – |
Sorafenib + erlotinib vs sorafenib + placebo | III | EGFR TKI | OS | 9.5 vs 8.5 months (p = 0.408) | 3.2 vs 4 months (p = 0.18) | 6.6 vs 3.9 (p = 0.102) |
Bevacizumab + Erlotinib | II | EGFR TKI Anti-VEGF | PFS | 13.7 months | 7.2 months | 24 |
Sorafenib + doxorubicin vs sorafenib alone | III | Multi-targeted TKI Cytotoxic agent | OS | 9.3 vs 10.5 months | 3.6 vs 3.2 months | – |
Bevacizumab | II | Anti-VEGF | PFS | – | 6.9 months | 13 |
Ramicirumab | II | Anti-VEGF | PFS | 12Â months | 4Â months | 9.5 |